-
One Disease, Many Paths: How Brain Wiring Shapes Huntington’s Symptoms
Latest News
-
Huntington’s disease therapeutics conference 2020 – Day 2
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
-
Huntington’s disease therapeutics conference 2020 – Day 1
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
-
Screening the entire genome for new drug targets for HD
Scientists screen the ENTIRE genome to find new potential therapeutic targets for HD. This ambitious study provides a wealth of data for HD researchers
-
The third dimension: using minibrains to understand brain development changes in HD
Researchers show that highly expanded CAGs in the HD gene can cause early developmental changes using 3D brain models called organoids. What’d they find?
-
Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement
Wave Life Sciences announces that its antisense drug WVE-120102 has lowered mutant huntingtin protein in cerebrospinal fluid, but investors seem disappointed. Rather confusing – what do we know for sure?
-
Could molecular handcuffs lower the protein that causes Huntington's disease?
Researchers got surprisingly lucky when looking for drug molecules to pull mutant huntingtin protein into a cellular garbage disposal machine
-
Exciting new Huntingtin lowering tool described
Exciting new Huntingtin Lowering work from @SangamoTx and @CHDIfoundation using "Zinc Fingers" to shut down expression of the mutant Huntingtin gene. More details on this exciting new technique here.
-
Details emerge of first Huntington’s disease gene therapy clinical trial
UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein using a ‘single-shot’ virus delivery system.
-
Fresh Updates from First Huntingtin Lowering Study Publication
Hot off the presses – New publication gives more details about the results of Ionis and Roche's safety study with a Huntingtin-lowering ASO
-
An Updated Trial Design for Roche's Huntingtin Lowering Trial
Roche announces an update to the GENERATION HD1 trial after reviewing the ASO open label extension study